Neurochemical dysfunction in treated and nontreated schizophrenia – a retrospective analysis of in vivo imaging studies

Different patterns of 5-HT receptor and transporter dysfunction in neuropsychiatric disorders – a comparative analysis of in vivo imaging findings

“…The outcome of the present analysis, which included findings obtained in 27 additional investigations, complements previous results on SERT, 5-HT 1 R and 5-HT 2 R function in AD, MDD, BD and SZ (Nikolaus et al, 2009(Nikolaus et al, , 2010(Nikolaus et al, , 2012(Nikolaus et al, , 2014a.…”

“…Data were evaluated as previously described (Nikolaus et al, 2010(Nikolaus et al, , 2012(Nikolaus et al, , 2014a. Percentual differences of SERT binding, 5-HT 1 R binding, 5-HT 2 R binding or 5-HT synthesis to the respective control groups of healthy individuals were computed for the following brain regions: STR (nucleus caudate, putamen), VS, globus pallidus (GP), THAL, HT, PFC (Brodmann areas 9-12, 46, 47 and 49), FC (PFC plus Brodmann areas 4 and 6), PC (Broadmann areas 3, 5, 7, 8, 39 and 40), TC (Brodmann areas 20-22, 38, 41 and 42), OC (Brodmann areas 17-19), CING, HIPP, PHG, AMYG, INS, EC, fusiform gyrus (FG), periaqueductal gray (PAG), MB (midbrain, pons) and cerebellum (CER).…”

“…No corrections were made for multiple comparisons. As implied by the outcome of our previous surveys on AD, MDD and SZ (Nikolaus et al, 2009(Nikolaus et al, , 2010(Nikolaus et al, , 2012(Nikolaus et al, , 2014a, significance tests were performed one-sidedly.…”

“…In recent surveys of all in vivo imaging studies, which, so far, had been conducted on 5-HTergic neurotransmission in acute AD, MDD, bipolar disorder (BD) and SZ (Nikolaus et al, 2010(Nikolaus et al, , 2012(Nikolaus et al, , 2014a, we found (1) a significant reduction of SERT in the MB of patients with AD relative to controls; (2) significant reductions of SERT in THAL and MB and a significant elevation of SERT in the insula (INS) of patients with MDD relative to controls; (3) significant elevations of SERT in CING and INS of depressed patients with BD relative to controls; (4) significant reductions of 5-HT 1A receptors (5-HT 1 R) in MB and CING of patients with AD relative to controls; (5) a significant reduction of 5-HT 1 R in the MB of patients with MDD relative to controls; (6) significant reductions of 5-HT 1 R in MB and temporal cortex (TC) of patients with SZ relative to controls; (7) significant reductions of 5-HT 2A receptors (5-HT 2 R) in prefrontal (PFC), frontal (FC), occipital cortex (OC) and CING of patients with MDD relative to controls; and (8) significant reductions of 5-HT 2 R in FC and TC of patients with SZ relative to controls.…”

Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms

“…Дофамин имеет несколько подтипов рецепторов: D1, D2, D3, D4, D5, но только D2, D3, D4 широко изуча-ются в области фармакогенетики. Антипсихотики снижа-ют передачу нервных импульсов в тех системах мозга, где их передатчиком является дофамин, в том числе в ответ-ственной за развитие экстрапирамидных побочных эф-фектов нигростриальной области [62,63]. Поэтому гене-тическая вариабельность рецепторов дофамина, влияю-щая на их плотность, экспрессию и активность, является важным фактором в регуляции индивидуального ответа на лечение.…”